• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Maxcyte Inc (NQ: MXCT )

    3.860 +0.100 (+2.66%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 314,140
    Open 3.730
    Bid (Size) 2.900 (1)
    Ask (Size) 4.000 (25)
    Prev. Close 3.760
    Today's Range 3.700 - 3.870
    52wk Range 3.150 - 5.545
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MaxCyte to Participate in Two Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Cynthia Collins to its Board of Directors
    From MaxCyte, Inc
    Via GlobeNewswire

    Performance

    YTD
    -22.80%
    -22.80%
    1 Month
    +2.12%
    +2.12%
    3 Month
    -11.06%
    -11.06%
    6 Month
    -1.28%
    -1.28%
    1 Year
    +10.29%
    +10.29%

    More News

    Read More
    MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
    From MaxCyte, Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
    From MaxCyte, Inc
    Via GlobeNewswire
    Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    Earnings Scheduled For March 12, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.